Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global High-Throughput Screening Market (2017-2022): Rise in Outsourced Drug Discovery Services - Research and Markets

Research and Markets
Posted on: 09 Nov 17

The "Global High-Throughput Screening Market - Growth, Trends and Forecasts 2017 - 2022" report has been added to Research and Markets' offering.

The global high-throughput screening (HTS) market is estimated to be USD 16.75 billion in 2016 and is projected to reach USD 22.68 billion by 2021, growing at a CAGR of 6.25% during the forecast period.

The global high-throughput screening market mainly comprises of target identification & validation, efficacy & safety screening, and monitoring of cell-based activity. High-throughput screening (HTS) is a popular approach to target validation, as it allows the assaying of a large number of potential biological modulators against a chosen set of defined targets. The screening test uses reflectivity measurements, quantifying the extent of binding of any logical entity (e.g. proteins, cells, animal embryo) with the base compound in the wells. The HTC technique can examine/screen 300,000 compounds a day, so it takes only a few weeks to screen millions of substances.

The global high-throughput screening market is mainly driven by the adoption of open innovation models by pharmaceutical companies to increase the use of high-throughput screening. Certain other factors include increasing drug discovery initiatives by academic and government institutions to boost the demand for high-throughput screening products, and huge capital investments in high-throughput screening technology by major firms, such as PerkinElmer, Beckman Coulter, and Tecan Group, among others. Private equity firms and venture capitalists are increasingly investing in the HTS market in countries, such as India, China, and Japan.

The increasing demand in research, huge capital investments in the HTS technology, the rise in outsourced drug discovery services, and increasing utilization rate of high-throughput screening technologies by pharmaceutical companies are key factors propelling the growth of the market. However, the capital-intensive nature, need for extensive automation techniques, and high regulatory intervention and costs are turning out to be restraints for the market. Many marketed drugs went off-patent in 2012.

Companies Mentioned:

  • Agilent Technologies, Inc. (U.S.)
  • PerkinElmer (U.S.)
  • Beckman Coulter, Inc.(U.S.)
  • Sigma-Aldrich Corporation (U.S.)
  • Tecan Group (Switzerland)
  • Axxam SpA (Italy)
  • Biacore International AB (Sweden)
  • Cerep SA (France)
  • Chemical Computing Group (Canada)
  • Council for Scientific and Industrial Research (CSIR) (The) (South Africa)
  • Kibron, Inc. (Finland)
  • Greiner Bio-One International AG (Austria)
  • GE Healthcare (UK)
  • Evotec AG (Germany)
  • CyBio AG (Germany)

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry Trends

6. Drivers, Restraints, Opportunities and Challenges Analysis

7. Global High Throughput Screening Market Segmentation

8. Global High throughput screening market by Geography - Regional shares and forecast

9. Competitive Landscape

10. Company Profiles

11. Analyst Outlook for Investment Opportunities

12. Future Outlook of the Market

For more information about this report visit https://www.researchandmarkets.com/research/46jpbq/global

View source version on businesswire.com: http://www.businesswire.com/news/home/20171109005780/en/

Business Wire
www.businesswire.com

Last updated on: 09/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.